Our Terms of Use and Privacy Policy have changed. We think you'll like them better this way.

Roger Graben, Kowa Pharmaceuticals, on acquisitions vs. licensing agreements

  • Broadcast in Health
  • 0 comments
WBR

WBR

×  

Follow This Show

If you liked this show, you should follow WBR.
h:81839
s:1433536
archived
The pharmaceutical industry thrives on fostering creative and productive partnerships. But when does a company decide to make the leap from a licensing agreement to an acquisition? That’s a question Kelly Hushin, Online Content Manager, Worldwide Business Research (WBR), producers of BioNetwork East, discusses here with Roger Graben, SVP, Operations & Business Development at Kowa America. BioNetwork East is a three-day event for biotech and pharmaceutical companies that facilitates partnering conversations through one-to-one meetings and networking. Roger is a speaker at the 2011 BioNetwork event, which takes place March 14 to 16 at the Edon-Roc Renaissance in Miami. You can visit the website at www.bionetworkeast.com to take a look at other speakers joining him.

Comments

 comments